(Q54541813)

English

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Multiple doses of sclerostin antibody romosozumab in healthy men and postmenopausal women with low bone mass: a randomized, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Desmond Padhi

1

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Mark Allison

2

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Alan J Kivitz

3

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Maria J Gutierrez

4

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Brian Stouch

5

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Christine Wang

6

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Graham Jang

7

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

publication date

11 December 2013

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

54

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

2

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

168-178

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Sclerostin: a gem from the genome leads to bone-building antibodies

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

A revised clinician's guide to the prevention and treatment of osteoporosis.

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Management of osteoporosis in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Effects of a single injection of teriparatide on bone turnover markers in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass

1 reference

https://api.crossref.org/works/10.1002%2FJCPH.239

21 January 2018

Identifiers

10.1002/JCPH.239

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

release_mq5e4twngnc73gquainnh4wyvu

1 reference

https://api.fatcat.wiki/v0/release/mq5e4twngnc73gquainnh4wyvu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

31 May 2018

http://europepmc.org/abstract/MED/24272917

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54541813&oldid=1843810727"